Return to QS5 Overview

Chronic Kidney Disease [QS5]

Measuring the use of this guidance

Statement: 1

People with risk factors for CKD are offered testing, and people with CKD are correctly identified

Quality standard measure: Proportion of people with risk factors for CKD who receive testing
What was measured: Proportion of patients with diabetes whose GP practices tested their serum creatinine levels on an annual basis
Data collection end: June 2016
85.9%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.
Quality standard measure: Proportion of people with risk factors for CKD who receive testing
What was measured: Proportion of patients with diabetes whose GP practices tested their urinary albumin/creatinine ratio on an annual basis
Data collection end: June 2016
53.9%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.

Statement: 2

People with CKD who may benefit from specialist care are referred for specialist assessment in accordance with NICE guidance

Quality standard measure: Proportion of people with CKD in defined at‑risk groups who are referred for specialist assessment
What was measured: Proportion of people with CKD in high risk groups who have a specialist referral recorded
Data collection end: June 2016
33.5%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.
Quality standard measure: Incidence of cardiovascular events for people with CKD.
What was measured: Hospitalisations due to acute and chronic ischaemic heart disease in people with coded and uncoded CKD stages 3-5.
Data collection end: June 2016
37.8%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.
Quality standard measure: Incidence of cardiovascular events for people with CKD.
What was measured: Hospitalisations due to cerebrovascular disease or TIA in people with coded and uncoded CKD stages 3-5.
Data collection end: June 2016
27.4%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.
Quality standard measure: Incidence of cardiovascular events for people with CKD.
What was measured: Hospitalisations due to heart failure in people with coded and uncoded CKD stages 3-5.
Data collection end: June 2016
27.1%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.
Quality standard measure: Incidence of cardiovascular events for people with CKD.
What was measured: Hospitalisations due to peripheral and aortic artery disease in people with coded and uncoded CKD stages 3-5.
Data collection end: June 2016
7.7%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.

Statement: 5

People with higher levels of proteinuria, and people with diabetes and microalbuminuria, are enabled to safely maintain their systolic blood pressure within a target range 120–129 mmHg and their diastolic blood pressure below 80 mmHg.

Quality standard measure: Proportion of people with higher levels of proteinuria with a recording of blood pressure in the previous 9 months, whose latest systolic blood pressure reading is in the range 120–129 mmHg and diastolic blood pressure below 80 mmHg
What was measured: Proportion of people with CKD stage 3 to 5 with diabetes who had a below target blood pressure reading recorded
Data collection end: June 2016
29.2%
Area covered: England and Wales
Source: National Chronic Kidney Disease Audit.

Statement: 6

People with CKD are assessed for disease progression.

Quality standard measure: Proportion of people with CKD who are assessed for disease progression in accordance with current NICE guidance.
What was measured: QOF CKD6: The percentage of patients on the CKD register whose notes have a record of a urine albumin: creatinine ratio (or protein: creatinine ratio) test in the previous 15 months
Data collection end: March 2011
82.2%
Data collection end: March 2012
82.2%
Data collection end: March 2013
81.8%
Area covered: National
Source: Health and Social Care Information Centre. Quality and Outcomes Framework.

 Return to QS5 Overview